Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218606 · ClinicalTrials.gov registry record · Phase 2
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 4
- Study locations
NCT02218606: Completed Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02218606 is a Phase 2 study of Prostate Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 81 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02218606, a Phase 2 study of Prostate Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to see what effects (good and bad) treatment with abiraterone acetate (an oral hormonal agent) and prednisone (a steroid) with and without cabazitaxel (a chemotherapy) have on the cancer and to find out more about whether specific laboratory tests on tumor are useful in predicting how the patient will respond to treatment.
Conditions Studied
Interventions
- DRUG Abiraterone acetate 1000 mg po daily
- DRUG Cabazitaxel 25 mg/m2 IV
- DRUG prednisone 5 mg po BID
Study Locations (4)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical Center - New York
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2014-08 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02218606
The ClinicalTrials.gov registry entry for NCT02218606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Abiraterone acetate 1000 mg po daily is the first listed.
NCT02218606 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT02218606 about?
NCT02218606 is a clinical study titled "Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer". The purpose of this study is to see what effects (good and bad) treatment with abiraterone acetate (an oral hormonal agent) and prednisone (a steroid) with and without cabazitaxel (a chemotherapy) have on the cancer and to find out more about whether specific laboratory tests on tumor are useful in ...
What is the current status of trial NCT02218606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2014-08. Estimated completion is 2023-10-13.
What conditions does trial NCT02218606 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02218606?
The interventions under investigation include: Abiraterone acetate 1000 mg po daily (DRUG), Cabazitaxel 25 mg/m2 IV (DRUG), prednisone 5 mg po BID (DRUG).
Who is sponsoring clinical trial NCT02218606?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02218606 being conducted?
This trial has 4 study locations across New York, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.